Styrene Butadene Styrene (SBS)
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
Global Relapsed Acute Myeloid Leukemia Drug Market Research Report 2024
1 Relapsed Acute Myeloid Leukemia Drug Market Overview
1.1 Product Overview and Scope of Relapsed Acute Myeloid Leukemia Drug
1.2 Relapsed Acute Myeloid Leukemia Drug Segment by Type
1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 aNK Program
1.2.3 AT-9283
1.2.4 BI-836858
1.2.5 Binimetinib
1.2.6 BL-8040
1.2.7 Others
1.3 Relapsed Acute Myeloid Leukemia Drug Segment by Application
1.3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Comparison by Application: (2022-2028)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Relapsed Acute Myeloid Leukemia Drug Market Size Estimates and Forecasts
1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue 2017-2028
1.4.2 Global Relapsed Acute Myeloid Leukemia Drug Sales 2017-2028
1.4.3 Relapsed Acute Myeloid Leukemia Drug Market Size by Region: 2017 Versus 2021 Versus 2028
2 Relapsed Acute Myeloid Leukemia Drug Market Competition by Manufacturers
2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers (2017-2022)
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Relapsed Acute Myeloid Leukemia Drug Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Relapsed Acute Myeloid Leukemia Drug Manufacturing Sites, Area Served, Product Type
2.5 Relapsed Acute Myeloid Leukemia Drug Market Competitive Situation and Trends
2.5.1 Relapsed Acute Myeloid Leukemia Drug Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Relapsed Acute Myeloid Leukemia Drug Players Market Share by Revenue
2.5.3 Global Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Relapsed Acute Myeloid Leukemia Drug Retrospective Market Scenario by Region
3.1 Global Relapsed Acute Myeloid Leukemia Drug Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Relapsed Acute Myeloid Leukemia Drug Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
3.3.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country
3.3.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
3.4.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country
3.4.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region
3.5.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
3.6.1 Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country
3.6.2 Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country
3.7.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Relapsed Acute Myeloid Leukemia Drug Historic Market Analysis by Type
4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2022)
4.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2017-2022)
4.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2017-2022)
5 Global Relapsed Acute Myeloid Leukemia Drug Historic Market Analysis by Application
5.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2022)
5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2017-2022)
5.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2017-2022)
6 Key Companies Profiled
6.1 4SC AG
6.1.1 4SC AG Corporation Information
6.1.2 4SC AG Description and Business Overview
6.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.1.5 4SC AG Recent Developments/Updates
6.2 AbbVie Inc.
6.2.1 AbbVie Inc. Corporation Information
6.2.2 AbbVie Inc. Description and Business Overview
6.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.2.5 AbbVie Inc. Recent Developments/Updates
6.3 Actinium Pharmaceuticals, Inc.
6.3.1 Actinium Pharmaceuticals, Inc. Corporation Information
6.3.2 Actinium Pharmaceuticals, Inc. Description and Business Overview
6.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.3.5 Actinium Pharmaceuticals, Inc. Recent Developments/Updates
6.4 Agios Pharmaceuticals, Inc.
6.4.1 Agios Pharmaceuticals, Inc. Corporation Information
6.4.2 Agios Pharmaceuticals, Inc. Description and Business Overview
6.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.4.5 Agios Pharmaceuticals, Inc. Recent Developments/Updates
6.5 Amgen Inc.
6.5.1 Amgen Inc. Corporation Information
6.5.2 Amgen Inc. Description and Business Overview
6.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.5.5 Amgen Inc. Recent Developments/Updates
6.6 Arog Pharmaceuticals, Inc.
6.6.1 Arog Pharmaceuticals, Inc. Corporation Information
6.6.2 Arog Pharmaceuticals, Inc. Description and Business Overview
6.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.6.5 Arog Pharmaceuticals, Inc. Recent Developments/Updates
6.7 Array BioPharma Inc.
6.6.1 Array BioPharma Inc. Corporation Information
6.6.2 Array BioPharma Inc. Description and Business Overview
6.6.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.7.5 Array BioPharma Inc. Recent Developments/Updates
6.8 Astellas Pharma Inc.
6.8.1 Astellas Pharma Inc. Corporation Information
6.8.2 Astellas Pharma Inc. Description and Business Overview
6.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.8.5 Astellas Pharma Inc. Recent Developments/Updates
6.9 Astex Pharmaceuticals, Inc.
6.9.1 Astex Pharmaceuticals, Inc. Corporation Information
6.9.2 Astex Pharmaceuticals, Inc. Description and Business Overview
6.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.9.5 Astex Pharmaceuticals, Inc. Recent Developments/Updates
6.10 AstraZeneca Plc
6.10.1 AstraZeneca Plc Corporation Information
6.10.2 AstraZeneca Plc Description and Business Overview
6.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.10.5 AstraZeneca Plc Recent Developments/Updates
6.11 AVEO Pharmaceuticals, Inc.
6.11.1 AVEO Pharmaceuticals, Inc. Corporation Information
6.11.2 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.11.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.11.5 AVEO Pharmaceuticals, Inc. Recent Developments/Updates
6.12 BioLineRx, Ltd.
6.12.1 BioLineRx, Ltd. Corporation Information
6.12.2 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.12.5 BioLineRx, Ltd. Recent Developments/Updates
6.13 Boehringer Ingelheim GmbH
6.13.1 Boehringer Ingelheim GmbH Corporation Information
6.13.2 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.13.5 Boehringer Ingelheim GmbH Recent Developments/Updates
6.14 Boston Biomedical, Inc.
6.14.1 Boston Biomedical, Inc. Corporation Information
6.14.2 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.14.5 Boston Biomedical, Inc. Recent Developments/Updates
6.15 Bristol-Myers Squibb Company
6.15.1 Bristol-Myers Squibb Company Corporation Information
6.15.2 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.15.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.16 Calithera Biosciences, Inc.
6.16.1 Calithera Biosciences, Inc. Corporation Information
6.16.2 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.16.5 Calithera Biosciences, Inc. Recent Developments/Updates
6.17 Celgene Corporation
6.17.1 Celgene Corporation Corporation Information
6.17.2 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.17.5 Celgene Corporation Recent Developments/Updates
6.18 Cornerstone Pharmaceuticals, Inc.
6.18.1 Cornerstone Pharmaceuticals, Inc. Corporation Information
6.18.2 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.18.5 Cornerstone Pharmaceuticals, Inc. Recent Developments/Updates
6.19 CTI BioPharma Corp.
6.19.1 CTI BioPharma Corp. Corporation Information
6.19.2 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Description and Business Overview
6.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2017-2022)
6.19.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
6.19.5 CTI BioPharma Corp. Recent Developments/Updates
7 Relapsed Acute Myeloid Leukemia Drug Manufacturing Cost Analysis
7.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
7.4 Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Relapsed Acute Myeloid Leukemia Drug Distributors List
8.3 Relapsed Acute Myeloid Leukemia Drug Customers
9 Relapsed Acute Myeloid Leukemia Drug Market Dynamics
9.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
9.2 Relapsed Acute Myeloid Leukemia Drug Market Drivers
9.3 Relapsed Acute Myeloid Leukemia Drug Market Challenges
9.4 Relapsed Acute Myeloid Leukemia Drug Market Restraints
10 Global Market Forecast
10.1 Relapsed Acute Myeloid Leukemia Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Relapsed Acute Myeloid Leukemia Drug by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Relapsed Acute Myeloid Leukemia Drug by Type (2023-2028)
10.2 Relapsed Acute Myeloid Leukemia Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Relapsed Acute Myeloid Leukemia Drug by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Relapsed Acute Myeloid Leukemia Drug by Application (2023-2028)
10.3 Relapsed Acute Myeloid Leukemia Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Relapsed Acute Myeloid Leukemia Drug by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Relapsed Acute Myeloid Leukemia Drug by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate Comparison by Type (2022-2028) & (K Pcs) & (US$ Million)
Table 2. Global Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate Comparison by Application (2022-2028) & (K Pcs) & (US$ Million)
Table 3. Global Relapsed Acute Myeloid Leukemia Drug Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Relapsed Acute Myeloid Leukemia Drug Market Competitive Situation by Manufacturers in 2021
Table 5. Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) of Key Manufacturers (2017-2022)
Table 6. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Relapsed Acute Myeloid Leukemia Drug Average Price (USD/Pcs) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Relapsed Acute Myeloid Leukemia Drug Manufacturing Sites and Area Served
Table 11. Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Relapsed Acute Myeloid Leukemia Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Relapsed Acute Myeloid Leukemia Drug as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2017-2022) & (K Pcs)
Table 16. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2017-2022)
Table 17. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2017-2022)
Table 19. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)
Table 20. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2017-2022)
Table 21. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2017-2022)
Table 23. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)
Table 24. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2017-2022)
Table 25. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region (2017-2022) & (K Pcs)
Table 28. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2017-2022)
Table 31. Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)
Table 32. Latin America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2017-2022)
Table 33. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2017-2022) & (K Pcs)
Table 36. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2017-2022)
Table 39. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2017-2022) & (K Pcs)
Table 40. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2017-2022)
Table 41. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2017-2022)
Table 43. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2017-2022) & (USD/Pcs)
Table 44. Global Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs) by Application (2017-2022)
Table 45. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2017-2022)
Table 46. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Application (2017-2022)
Table 48. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2017-2022) & (USD/Pcs)
Table 49. 4SC AG Corporation Information
Table 50. 4SC AG Description and Business Overview
Table 51. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 52. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product
Table 53. 4SC AG Recent Developments/Updates
Table 54. AbbVie Inc. Corporation Information
Table 55. AbbVie Inc. Description and Business Overview
Table 56. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 57. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 58. AbbVie Inc. Recent Developments/Updates
Table 59. Actinium Pharmaceuticals, Inc. Corporation Information
Table 60. Actinium Pharmaceuticals, Inc. Description and Business Overview
Table 61. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 62. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 63. Actinium Pharmaceuticals, Inc. Recent Developments/Updates
Table 64. Agios Pharmaceuticals, Inc. Corporation Information
Table 65. Agios Pharmaceuticals, Inc. Description and Business Overview
Table 66. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 67. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 68. Agios Pharmaceuticals, Inc. Recent Developments/Updates
Table 69. Amgen Inc. Corporation Information
Table 70. Amgen Inc. Description and Business Overview
Table 71. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 72. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 73. Amgen Inc. Recent Developments/Updates
Table 74. Arog Pharmaceuticals, Inc. Corporation Information
Table 75. Arog Pharmaceuticals, Inc. Description and Business Overview
Table 76. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 77. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 78. Arog Pharmaceuticals, Inc. Recent Developments/Updates
Table 79. Array BioPharma Inc. Corporation Information
Table 80. Array BioPharma Inc. Description and Business Overview
Table 81. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 82. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 83. Array BioPharma Inc. Recent Developments/Updates
Table 84. Astellas Pharma Inc. Corporation Information
Table 85. Astellas Pharma Inc. Description and Business Overview
Table 86. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 87. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 88. Astellas Pharma Inc. Recent Developments/Updates
Table 89. Astex Pharmaceuticals, Inc. Corporation Information
Table 90. Astex Pharmaceuticals, Inc. Description and Business Overview
Table 91. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 92. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 93. Astex Pharmaceuticals, Inc. Recent Developments/Updates
Table 94. AstraZeneca Plc Corporation Information
Table 95. AstraZeneca Plc Description and Business Overview
Table 96. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 97. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product
Table 98. AstraZeneca Plc Recent Developments/Updates
Table 99. AVEO Pharmaceuticals, Inc. Corporation Information
Table 100. AVEO Pharmaceuticals, Inc. Description and Business Overview
Table 101. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 102. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 103. AVEO Pharmaceuticals, Inc. Recent Developments/Updates
Table 104. BioLineRx, Ltd. Corporation Information
Table 105. BioLineRx, Ltd. Description and Business Overview
Table 106. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 107. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product
Table 108. BioLineRx, Ltd. Recent Developments/Updates
Table 109. Boehringer Ingelheim GmbH Corporation Information
Table 110. Boehringer Ingelheim GmbH Description and Business Overview
Table 111. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 112. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product
Table 113. Boehringer Ingelheim GmbH Recent Developments/Updates
Table 114. Boston Biomedical, Inc. Corporation Information
Table 115. Boston Biomedical, Inc. Description and Business Overview
Table 116. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 117. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 118. Boston Biomedical, Inc. Recent Developments/Updates
Table 119. Bristol-Myers Squibb Company Corporation Information
Table 120. Bristol-Myers Squibb Company Description and Business Overview
Table 121. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 122. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product
Table 123. Bristol-Myers Squibb Company Recent Developments/Updates
Table 124. Calithera Biosciences, Inc. Corporation Information
Table 125. Calithera Biosciences, Inc. Description and Business Overview
Table 126. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 127. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 128. Calithera Biosciences, Inc. Recent Developments/Updates
Table 129. Celgene Corporation Corporation Information
Table 130. Celgene Corporation Description and Business Overview
Table 131. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 132. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product
Table 133. Celgene Corporation Recent Developments/Updates
Table 134. Cornerstone Pharmaceuticals, Inc. Corporation Information
Table 135. Cornerstone Pharmaceuticals, Inc. Description and Business Overview
Table 136. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 137. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product
Table 138. Cornerstone Pharmaceuticals, Inc. Recent Developments/Updates
Table 139. CTI BioPharma Corp. Corporation Information
Table 140. CTI BioPharma Corp. Description and Business Overview
Table 141. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
Table 142. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product
Table 143. CTI BioPharma Corp. Recent Developments/Updates
Table 144. Production Base and Market Concentration Rate of Raw Material
Table 145. Key Suppliers of Raw Materials
Table 146. Relapsed Acute Myeloid Leukemia Drug Distributors List
Table 147. Relapsed Acute Myeloid Leukemia Drug Customers List
Table 148. Relapsed Acute Myeloid Leukemia Drug Market Trends
Table 149. Relapsed Acute Myeloid Leukemia Drug Market Drivers
Table 150. Relapsed Acute Myeloid Leukemia Drug Market Challenges
Table 151. Relapsed Acute Myeloid Leukemia Drug Market Restraints
Table 152. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Type (2023-2028) & (K Pcs)
Table 153. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Type (2023-2028)
Table 154. Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 155. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Type (2023-2028)
Table 156. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Application (2023-2028) & (K Pcs)
Table 157. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Application (2023-2028)
Table 158. Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 159. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Application (2023-2028)
Table 160. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecast by Region (2023-2028) & (K Pcs)
Table 161. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share Forecast by Region (2023-2028)
Table 162. Global Relapsed Acute Myeloid Leukemia Drug Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 163. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Region (2023-2028)
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Relapsed Acute Myeloid Leukemia Drug
Figure 2. Global Relapsed Acute Myeloid Leukemia Drug Market Share by Type in 2021 & 2028
Figure 3. aNK Program Product Picture
Figure 4. AT-9283 Product Picture
Figure 5. BI-836858 Product Picture
Figure 6. Binimetinib Product Picture
Figure 7. BL-8040 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Relapsed Acute Myeloid Leukemia Drug Market Share by Application in 2021 & 2028
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Relapsed Acute Myeloid Leukemia Drug Market Size (2017-2028) & (US$ Million)
Figure 15. Global Relapsed Acute Myeloid Leukemia Drug Sales (2017-2028) & (K Pcs)
Figure 16. Relapsed Acute Myeloid Leukemia Drug Sales Share by Manufacturers in 2021
Figure 17. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers in 2021
Figure 18. The Global 5 and 10 Largest Relapsed Acute Myeloid Leukemia Drug Players: Market Share by Revenue in 2021
Figure 19. Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 20. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2017-2022)
Figure 21. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region in 2021
Figure 22. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2017-2022)
Figure 23. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region in 2021
Figure 24. U.S. Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Canada Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Germany Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. France Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. U.K. Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Italy Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Russia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Japan Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. South Korea Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. India Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Australia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Taiwan Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Indonesia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Thailand Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Malaysia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Philippines Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Vietnam Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Mexico Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Argentina Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 47. UAE Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 48. Sales Market Share of Relapsed Acute Myeloid Leukemia Drug by Type (2017-2022)
Figure 49. Manufacturing Cost Structure of Relapsed Acute Myeloid Leukemia Drug
Figure 50. Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
Figure 51. Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
4SC AG AbbVie Inc. Actinium Pharmaceuticals, Inc. Agios Pharmaceuticals, Inc. Amgen Inc. Arog Pharmaceuticals, Inc. Array BioPharma Inc. Astellas Pharma Inc. Astex Pharmaceuticals, Inc. AstraZeneca Plc AVEO Pharmaceuticals, Inc. BioLineRx, Ltd. Boehringer Ingelheim GmbH Boston Biomedical, Inc. Bristol-Myers Squibb Company Calithera Biosciences, Inc. Celgene Corporation Cornerstone Pharmaceuticals, Inc. CTI BioPharma Corp.